Rationale: Cigarette smoking is a risk factor for diffuse parenchymal lung disease. Risk factors for subclinical parenchymal lung disease have not been described. Objectives: To determine if cigarette smoking is associated with subclinical parenchymal lung disease, as measured by spirometric restriction and regions of high attenuation on computed tomography (CT) imaging. Methods: We examined 2,563 adults without airflow obstruction or clinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis, a population-based cohort sampled from six communities in the United States. Cumulative and current cigarette smoking were assessed by pack-years and urine cotinine, respectively. Spirometric restriction was defined as a forced vital capacity less than the lower limit of normal. High attenuation areas on the lung fields of cardiac CT scans were defined as regions having an attenuation between 2600 and 2250 Hounsfield units, reflecting ground-glass and reticular abnormalities. Generalized additive models were used to adjust for age, gender, race/ethnicity, smoking status, anthropometrics, center, and CT scan parameters. Measurements and Main Results: The prevalence of spirometric restriction was 10.0% (95% confidence interval [CI], 8.9-11.2%) and increased relatively by 8% (95% CI, 3-12%) for each 10 cigarette pack-years in multivariate analysis. The median volume of high attenuation areas was 119 cm 3 (interquartile range, 100-143 cm 3 ). The volume of high attenuation areas increased by 1.6 cm 3 (95% CI, 0.9-2.4 cm 3 ) for each 10 cigarette pack-years in multivariate analysis. Conclusions: Smoking may cause subclinical parenchymal lung disease detectable by spirometry and CT imaging, even among a generally healthy cohort.
The diffuse parenchymal lung diseases (DPLDs) are characterized by fibrosis and inflammation of the lung parenchyma, areas of high attenuation on computed tomography (CT) scan, and reduced FVC (1) . Although some DPLDs are treatable, the most common idiopathic form of DPLD, idiopathic pulmonary fibrosis (IPF), has no proven therapies and carries a uniformly high mortality rate (2, 3) . Identification of risk factors for IPF and other DPLDs might allow for the development of preventative strategies.
Cigarette smoking is a putative risk factor for some of the idiopathic interstitial pneumonias. For example, case series and clinical experience suggest that desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease are strongly linked to cigarette smoking (4, 5) . Cigarette smoking has also been associated with a greater risk for IPF in some (6) (7) (8) (9) (10) but not all studies (11, 12) . Each of these studies is limited by casecontrol design and largely unadjusted analyses. Most also preceded the modern understanding of this disease (2, 6-8, 11, 12) .
Asymptomatic, early parenchymal lung disease has been increasingly recognized and reported in family members of affected individuals (10, (13) (14) (15) (16) . To date, however, only one population-based study has examined risk factors for subclinical parenchymal lung disease. In the U.S. National Health and Nutrition Examination Survey (NHANES) I, current smokers had an increased risk for spirometric restriction (reduced FVC in the absence of airflow obstruction) compared with never smokers, but former smokers had no increased risk; associations with cumulative smoking (pack-years) were not reported (17) . Although suggestive, spirometric restriction has many possible causes, only one of which is parenchymal lung disease.
In recent years, CT imaging has become the gold standard noninvasive test to diagnose DPLD (1) . Unlike spirometry, CT imaging of the lungs has not generally been available in population-based cohorts, despite the development of powerful
AT A GLANCE COMMENTARY Scientific Knowledge on the Subject
Cigarette smoking is a risk factor for some idiopathic interstitial pneumonias, and current smokers have a higher prevalence of spirometric restriction. There are no population-based cohort studies examining the association between cigarette smoking and increased lung density on computed tomography (CT).
What This Study Adds to the Field
Smoking may cause subclinical parenchymal lung disease detectable by spirometry and CT imaging. tools for quantitating parenchymal lung disease noninvasively with CT (18) . The Multi-Ethnic Study of Atherosclerosis (MESA) is a population-based prospective cohort study that enrolled older adults without clinical cardiovascular disease. MESA participants underwent cardiac CT scanning that imaged most of the lung parenchyma, offering the opportunity to identify risk factors for subclinical parenchymal lung disease.
Therefore, we examined the relationships between cigarette smoking, spirometric restriction, and increased lung attenuation by CT imaging in MESA. We hypothesized that a greater number of pack-years of cigarette smoking would be associated with a higher prevalence of spirometric restriction and a greater volume of high CT attenuation in the lung parenchyma independent of obesity and other potential confounding factors in participants without evidence of airflow obstruction. Some of the results of this study have been previously reported in the form of an abstract (19) .
METHODS

MESA
MESA is a multicenter prospective cohort study to investigate the prevalence, correlates, and progression of subclinical cardiovascular disease in individuals without clinical cardiovascular disease (http:// www.mesa-nhlbi.org) (20) . In 2000 to 2002, MESA recruited 6,814 men and women aged 45 to 84 years old from six United States communities: Forsyth County, NC; northern New York County and Bronx County, NY; Baltimore City and Baltimore County, MD; St. Paul, MN; Chicago, IL; and Los Angeles, CA. MESA participants are white, African American, Hispanic, or Asian (mostly of Chinese origin). Exclusion criteria included clinical cardiovascular disease, weight greater than 136 kg, any impediment to long-term participation, and chest CT within the past year. The protocols of MESA and all studies described herein were approved by the Institutional Review Boards of all collaborating institutions and the National Heart, Lung, and Blood Institute. Chinese Americans were over-sampled to improve the precision of estimates for this group.
In the current study, we excluded 72 participants who did not complete spirometry, 180 with less than two acceptable spirometry maneuvers, 231 who did not reach a volume-time plateau, 756 with airflow obstruction (an FEV 1 /FVC ratio less than 0.70), and 163 with incomplete data for pack-years or cotinine.
Spirometry
Spirometry was performed according to American Thoracic Society/ European Respiratory Society guidelines (see online supplement) (21) . We defined spirometric restriction as an FVC less than the lower limit of normal according to NHANES III race-specific reference equations (22) . Because references equations for Asian Americans were not available from the NHANES III study, we used a 0.88 correction factor for the predicted FVC for Chinese Americans (23) .
Lung Attenuation on CT Scan
Quantitative measures of lung attenuation were performed on the lung fields of MESA cardiac CT scans, which image approximately 70% of the lung volume from the carina to lung bases (24) . CT scans were performed during the years 2000 to 2002 on multidetector CT scanners (three sites) and electron beam tomography scanners (three sites) using a standardized protocol (25) . Two sequential scans on separate breathholds were performed in succession at full inspiration on each participant. The scan with higher air volume was used for analyses, except in cases of discordant scan quality control score, in which case the higher-quality scan was used (24) . Image attenuation was assessed using a modified version of the Pulmonary Analysis Software Suite (26) (27) (28) (29) at a single reading center by trained readers without knowledge of smoking history. Scanner calibration methods in MESA for coronary calcium have been previously published (25) and are described in the online supplement. To account for variation in scanner calibration at 21,000 Hounsfield units (HU), attenuation of air outside the body was measured for each scan and the attenuation of each pixel was corrected to have the value: (21,000 3 measured pixel attenuation)/mean air attenuation.
CT Definition of Subclinical Parenchymal Lung Disease
We are not aware of an established definition of either DLPD or subclinical parenchymal lung disease using quantitative CT measures. Therefore, we defined subclinical parenchymal lung disease as high attenuation areas (HAAs) within the lung fields having a CT attenuation value between 2600 and 2250 HU (Figure 2 ). This range of CT lung attenuation includes ground-glass and reticular abnormalities and is low enough to clearly exclude more dense areas, such as complete atelectasis, medium and large blood vessels, and pulmonary nodules, which are all more dense than water (HU of 0) (30, 31) . The intraclass correlation coefficient of HAA among the 100% replicate CT scans was 0.93 (n 5 2,653).
We validated HAA expressed as a percentage of the total lung volume imaged on cardiac CT scans against full-lung CT scans in 42 MESA participants. The Spearman correlation coefficient of HAA between cardiac and full-lung scans was 0.87 and the mean difference was 0.2% (95% limits of agreement 22.5 to 13.0%).
A board-certified thoracic radiologist and a board-certified pulmonologist independently reviewed the lung fields of 101 CT scans sampled randomly among participants with greater than 10% HAA by volume (95th percentile of HAA) and less than 10% HAA. Reviewers were blinded to the HAA values of the scans and were not permitted to quantify voxel attenuation using imaging software.
Statistical Analysis
For descriptive purposes, the cohort was stratified by pack-years of cigarette smoking. We estimated prevalence ratios using Poisson regression with robust standard errors in generalized linear models (32) . All continuous variables had linear relationships with the natural log prevalence of spirometric restriction. For the lung attenuation analysis, generalized additive models with loess smoothing functions for continuous variables were used to allow for the flexible specification of relationships and to minimize misspecification of potential confounding variables. The volume of HAAs was regressed on pack-years controlling for the total volume of imaged lung and other covariates. We chose this approach instead of expressing HAA as a percentage of the imaged lung volume because the latter approach specifies the dependent variable as a ratio, which may induce spurious correlations (33) . Statistical significance was defined as two-tailed P values less than 0.05. Analyses were performed using SAS 9.1 (SAS Institute, Cary, NC) and the gam function in R 2.6 (R Foundation, Vienna, Austria).
RESULTS
The mean age of the 2,563 participants was 64 6 9 years, and 44% were men. Thirty-three percent were white, 24% were African American, 25% were Hispanic, and 18% were Chinese American. Eight percent were current and 37% were former smokers, with a median number of cigarette pack-years of 15 (interquartile range 5-31). Participants with heavier smoking histories were more likely to be white, male, and obese (Table 1) .
Spirometric Restriction
The prevalence of spirometric restriction was 10.0% (95% confidence interval [CI], 8.9-11.2%) overall and was highest among the heaviest smokers (Table 2) . After adjustment for demographics, the prevalence of spirometric restriction increased by 10% for every 10 cigarette pack-years smoked (95% CI, 7-14%). Additional adjustment for smoking status, urine cotinine level, and anthropometrics did not meaningfully change this association. The nonlinear model ( Figure 3A ) did not fit the data better than the linear model, suggesting that the relationship between pack-years and spirometric restriction was linear.
Similarly, a higher urine cotinine concentration was associated with a greater prevalence of spirometric restriction even after adjusting for demographics, cigarette pack-years, and anthropometrics (5% increase in the prevalence of spirometric restriction per 1 mg/ml increase in urine cotinine; 95% CI, 1-9%; Table 3 ).
HAAs
HAA greater than 10% was sensitive and specific for areas of high attenuation suggestive of clinically relevant abnormalities identified by visual readings. Sensitivity of HAA greater than 10% was 81 and 78% compared with qualitative readings by a board-certified thoracic radiologist and board-certified pulmonologist, respectively. Specificity of HAA greater than 10% was 64 and 91%, respectively. Interobserver agreement was 71% and interobserver k was 0.45. After excluding scans with breath artifacts, k was 0.60. Among the 56 scans with greater than 10% HAA, the most common abnormalities detected were ground-glass opacities or atelectasis (radiologist: 34, pulmonologist: 52), reticular abnormalities (radiologist: 2, pulmonologist: 5), possible or probable usual interstitial pneumonia pattern (radiologist: 6, pulmonologist: 1), definite usual interstitial pneumonia (UIP) pattern (radiologist: 1, pulmonologist: 0), and focal scar (radiologist: 5, pulmonologist: 3). Figure 2 shows histograms of CT lung attenuation and representative CT images of the lungs from three study subjects at the median (119 cm 3 ), 75th percentile (143 cm 3 ), and 95th percentile (202 cm 3 ) of HAA. HAA was greater among those with spirometric restriction compared with those with normal spirometry (age-, sex-, and race-adjusted mean difference of 5.0 cm 3 , 95% CI 0.1 to 9.9 cm 3 ; P 5 0.04).
HAA increased across categories of pack-years (Table 2) . After adjusting for demographics, HAA increased by 2.5 cm 3 (95% CI, 1.8-3.3 cm 3 ) for each 10 cigarette pack-years. Additional adjustment for smoking status, urine cotinine, and anthropometrics attenuated this association, but it remained significant in the fully adjusted model. The nonlinear model ( Figure 3B ) did not fit the data better than the linear model, suggesting that the relationship between pack-years and HAA was linear. A fully adjusted model limited to former and never smokers showed similar findings (mean increase of 1.8 cm 3 of HAAs per 10 cigarette pack-years; 95% CI, 1.0-2.7; n 5 2,253). Limiting the fully adjusted model to the subgroup with normal body mass index (20-25 kg/m 2 ) showed similar results (mean increase of 2.8 cm 3 of HAAs per 10 cigarette pack-years; 95% CI, 1.5-4.2 cm 3 ; n 5 654).
A higher urine cotinine level was also associated with a greater volume of high lung attenuation even after adjusting for demographics, cigarette pack-years, and anthropometrics (mean increase of 2.0 cm 3 of HAAs per 1 mg/ml increase in urine cotinine; 95% CI, 1.4-2.7 cm 3 ; Table 3 ).
Additional Analyses
Additional analyses are presented in Table E2 in the online data supplement. Decreased kurtosis and skewness of the lung histogram are characteristically observed in patients with DPLD and correlate with measures of disease severity (30) . In our study, greater cigarette pack-years were associated with decreased kurtosis and skewness (Table E2) .
We also explored the effect of potential confounders on our results (Table E2) . Neither stratification by type of CT scanner nor exclusion of scans of suboptimal quality affected our findings. Exclusion of those with chest wall or pleural disease alone (n 5 39) or those with any self-reported chest disease (n 5 100) did not change our findings. Similarly, exclusion of participants with reduced left ventricular function or wall motion abnormalities; occupational exposure to dusts, gases, or fumes; tricyclic antidepressant use; coronary artery calcification; or obesity led to similar results (Table E2) .
Inclusion of 350 participants with an FEV 1 /FVC ratio less than 0.70 but greater than the lower limit of normal gave similar Table E1 in the online data supplement.
results (22) . Inclusion of 715 participants with airflow obstruction did not alter our findings.
In a post hoc analysis, the association between pack-years and CT lung attenuation was different for men compared with women. The mean increase in HAA per 10 pack-years was 2.3 cm 3 (95% CI, 1.4-3.3 cm 3 ) for men compared with 0.6 cm 3 (95% CI, 20.6 to 1.9 cm 3 ) for women (P for interaction 5 0.005) in fully adjusted models. We did not detect a similar gender difference for the association of pack-years with spirometric restriction.
DISCUSSION
This is the first study to examine the association between cumulative cigarette smoking and areas of increased lung attenuation on CT in a large population-based cohort. To do so, we defined a novel measure of increased CT lung attenuation, HAA, that accurately predicts the presence of parenchymal lung abnormalities. Higher HAA and spirometric restriction were both associated with a greater number of pack-years of cigarettes smoked independent of body size, current smoking status, and other potential confounders. Our findings support the hypothesis that cigarette smoking is a risk factor for parenchymal lung abnormalities other than emphysema.
Mannino and coworkers previously identified current smoking status as an independent risk factor for spirometric re- Prevalence ratios are from generalized linear models. Mean increases are from generalized additive models with loess smoothers for continuous covariates. Linear estimates are presented. The full multivariate model includes age, sex, race/ethnicity, cigarette pack-years, height, body mass index, hip circumference, and waist circumference. All HAA models are further adjusted for study site, total volume of imaged lung, and milliampere dose.
* HAAs are regions of lung with an attenuation between 2600 and 2250 Hounsfield units. striction in 4,320 participants in the NHANES I study (17) , a finding we confirmed using urine cotinine, a biological marker of current smoking. In the NHANES study, current smoking was associated with a 40% increased odds of spirometric restriction after adjusting for potential confounders, an effect estimate similar in magnitude to the 40% increase in the prevalence of spirometric restriction we detected in heavy smokers (.20 pack-years) compared with never smokers. Our study builds on this important previous work by showing that cumulative cigarette smoke exposure is associated with spirometric restriction and areas of increased lung attenuation on CT independent of current smoking status, providing the first evidence that cigarette smoking might lead directly to increases in lung density even without a formal diagnosis of DPLD.
The increased HAA we observed in heavy smokers might represent pathological changes in the lung, such as interstitial inflammation or fibrosis. Despite a number of case-control studies linking cigarette smoking to IPF (6-9), the mechanisms underlying this association are not well established. Cigarette smoke can injure endothelial and alveolar epithelial cells by increasing oxidative stress (34) (35) (36) and enhancing virus-induced parenchymal inflammation (37) . Such injury could lead to abnormal wound healing and parenchymal fibrosis in susceptible individuals. In an animal model, cigarette smoke also increases the number of pulmonary myofibroblasts and enhances the fibrotic response to bleomycin, possibly by increasing matrix metalloproteinase-9 levels (38), and may further promote fibrosis by stimulating release of transforming growth factor-b1 from fibroblasts (39) . Our findings should direct additional effort toward understanding the role of cigarette smoking in the development of pulmonary parenchymal fibrosis and inflammation.
Cigarette smoke is also a well-known cause of airway changes, such as mucous hypersecretion, airway inflammation, and increases in airway wall thickness. The airways of cigarette smokers are characterized by increases in inflammatory cells, which can persist after smoking cessation (40) . We excluded large airways from our quantitative assessment of CT lung density, minimizing the impact of airway inflammation on our findings. Small-airway inflammation and bronchiolocentric fibrosis, however, may have contributed to our results. Nevertheless, because our findings were unchanged by the exclusion of current smokers, it is unlikely that respiratory bronchiolitis or alveolar macrophage accumulation completely accounts for our findings.
Pulmonary edema also increases lung attenuation. Cigarette smoking could increase lung water by affecting left ventricular function. However, clinical cardiovascular disease, including heart failure, was an exclusion criterion, and our results remained unchanged after excluding those with decreased left ventricular function or wall motion abnormalities, minimizing the likelihood that our findings represent increases in pulmonary edema.
Our study had several limitations. First, we retrospectively ascertained cigarette pack-years and smoking status, introducing the potential for information bias. To minimize misclassification of these key exposures, we ascertained the number of cigarette pack-years using standardized and supplemental methods and measured urine cotinine, an established indicator of recent tobacco smoke exposure (41) .
Second, although smoking is an established risk factor for chronic obstructive pulmonary disease its association with DPLD is less certain; unmeasured confounders could be responsible for some or all of the associations we observed. For example, obesity is a frequent cause of reductions in lung volume due to changes in chest wall compliance and diaphragmatic efficiency (42) (43) (44) (45) , and abdominal obesity has recently been shown to be a critical factor contributing to spirometric restriction (46) . In our study, obesity was associated with cigarette smoking. To avoid confounding by body size, we used flexible modeling of precisely measured anthropometric factors, such as body mass index, height, and hip and waist circumferences, and we found consistent results among participants with a normal body mass index. Nonetheless, residual confounding by body size cannot be entirely excluded. The lack of putative risk factors for IPF and other idiopathic interstitial pneumonias limits our ability to examine additional confounding factors.
Third, static lung volumes were not measured in MESA. A restrictive ventilatory defect is defined as ''a reduction in total lung capacity below the 5th percentile of the predicted value, and a normal FEV 1 /vital capacity'' and therefore requires measurement of lung volumes by plethysmography, gas dilution, or gas washout techniques (47) . Among patients referred to a pulmonary function laboratory, spirometric restriction is associated with a low total lung capacity only about half of the Figure 3 . Continuous relationships of cigarette pack-years to (A) spirometric restriction and (B) the volume of high lung attenuation. Thick dotted lines: smoothed regression lines adjusted for age, gender, race/ethnicity, current smoking status, urine cotinine, height, body mass index, and waist and hip circumferences. B is further adjusted for study site, total volume of imaged lung, and milliampere dose. Thin solid lines: 95% confidence intervals. Neither smoothed curve differed significantly from a straight line (A: P 5 0.65; B: P 5 0.16), suggesting that the relationships between cigarette pack-years and both measures are linear. Multivariate-adjusted (predicted) probabilities of spirometric restriction were estimated by combining the prevalence of spirometric restriction in the sample with the predicted incremental probabilities of spirometric restriction using a generalized additive model. Multivariate-adjusted (predicted) values of HAA were estimated by adding the sample mean to predicted mean differences using a generalized additive model. time (48, 49) . On the other hand, CT measures are particularly sensitive for changes in the pulmonary parenchyma, and our findings were consistent across both measures of subclinical parenchymal lung disease.
Fourth, we created a new measure, HAA, for epidemiologic research, because there is no current standard. We chose a reasonable range of lung density (2600 to 2250 HU) that represents typical ground-glass opacities and interstitial thickening, while clearly excluding areas devoid of air, such as complete atelectasis and consolidation (31) . While scanning during diaphragmatic motion or incomplete inspiration can also lead to areas of increased lung attenuation, our results remained unchanged after excluding scans of suboptimal quality. Our measure was highly reproducible between scans and showed moderate agreement between expert reviewers. In addition, findings for the alternative measures of kurtosis and skewness showed consistency with our new measure and with previous studies of interstitial disease (30) .
Fifth, although we ascertained CT lung attenuation using partial lung scans obtained to assess coronary calcium, most idiopathic DPLDs preferentially involve the lower lobes, which were virtually completely imaged. In addition, our new measure correlated strongly with measures from full-lung CT scans.
Finally, the association between cigarette pack-years and HAAs was relatively small: the increase in HAAs for each 10 cigarette pack-years was equal in magnitude to 4% of its standard deviation. An association of this magnitude should be expected in a healthy cohort, likely representing subclinical parenchymal changes. Larger effect sizes might be expected only in those with clinical DPLD.
In conclusion, we found that cumulative and current cigarette smoking were both independently associated with spirometric restriction and increased CT lung attenuation in a populationbased sample of older adults without airflow obstruction or clinical cardiovascular disease. Our findings support the hypothesis that smoking is a risk factor for subclinical parenchymal inflammation and/or fibrosis.
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